JournalsHub
.online
Find My Journal
AA

Anne Armstrong

University of Manchester GB

ORCID 0000-0002-0774-7006
356
Publications
12,884
Citations
42
H-Index
88
i10-Index
3.41
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation OA
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek +9 more
New England Journal of Medicine 2017
3,133
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial OA
Adrian Murray Brunt, Joanne Haviland, Duncan Wheatley, Mark Sydenham, Abdulla Alhasso +51 more
The Lancet 2020
1,035
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer OA
Mark E. Robson, Nadine Tung, Pierfranco Conté, Seock‐Ah Im, Elżbieta Senkus +9 more
Annals of Oncology 2019
741
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Sylvia Adams, Sherene Loi, Deborah Toppmeyer, David W. Cescon, Michelino De Laurentiis +15 more
Annals of Oncology 2018
620
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study OA
Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey, Sarah Briggs, Roland Arnold +95 more
The Lancet Oncology 2020
599

Publications

353 total

UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer

J. McKeon, E. Daniels, A. Halstead, C. Machado, S. Potter - ESMO Real World Data and Digital Oncology, 2026
Cited by 0 Semantic Scholar

Acute presentations in neoadjuvant chemotherapy/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data

Tim Cooksley, Safwaan Adam, B. Nagy, Sophie Raby, A. Armstrong - Breast, 2025
Cited by 0 Semantic Scholar

Abstract P2-11-21: Characterisation of treatment and outcomes for adenoid cystic carcinoma as a distinct clinical sub-type of triple negative breast cancer

F. Britton, S. Churchill, P. Bishop, G. Betts, J. Haigh - Clinical Cancer Research, 2025
Cited by 0 Semantic Scholar

Immune Checkpoint Inhibitor related Haemophagocytic Lymphohistiocytosis (HLH) in triple negative breast cancer: a case series.

Tim Cooksley, J.M.J. Weaver, B. Nagy, A. Armstrong - QJM : monthly journal of the Association of Physicians, 2025
Cited by 0 Semantic Scholar

Enhancing the breast cancer workforce: Introducing the role of the GPCR (General Practitioner with Cancer Role)

Clare Garnsey, Claire Goldrick, S. Lilley, A. Armstrong - European Journal of Surgical Oncology, 2025
Cited by 0 Semantic Scholar

Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?

Jamie M. J. Weaver, B. Nagy, Caroline Wilson, A. Lewis, A. Armstrong - Supportive Care in Cancer, 2025
Cited by 2 Semantic Scholar

Development and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer.

N. L. Brown, Ann Tivey, Suzanne Frank, S.C. Phua, Jack E. Johnson - Clinical Breast Cancer, 2024
Cited by 2 Semantic Scholar

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial PDF

Fabrice André, Yeon Hee Park, Sung‐Bae Kim, Toshimi Takano, Seock‐Ah Im et al. - The Lancet, 2023
Cited by 324 OpenAlex

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer PDF

Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada et al. - Annals of Oncology, 2022
Cited by 416 OpenAlex

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer PDF

Nicholas C. Turner, Claire Swift, Ben Jenkins, Lucy Kilburn, Maria Coakley et al. - Annals of Oncology, 2022
Cited by 180 OpenAlex

Research Topics

Advanced Breast Cancer Therapies (138) HER2/EGFR in Cancer Research (98) Cancer Treatment and Pharmacology (67) Estrogen and related hormone effects (41) BRCA gene mutations in cancer (37)

Frequent Co-Authors

SU
Susan Cleator
5 joint publications
SE
Seock‐Ah Im
4 joint publications
NO
Norikazu Masuda
4 joint publications
SU
Suzette Delaloge
4 joint publications
JU
Judith M. Bliss
4 joint publications
EL
Elżbieta Senkus
3 joint publications

Affiliations

AstraZeneca (United Kingdom)
GB 2019 - 2018
University of Southern California
US 2019 - 2019
National Health Service
GB 2019 - 2019
National Institutes of Health
US 2011 - 2011
Memorial Sloan Kettering Cancer Center
US 2018 - 2018

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now